Kura Oncology, Inc. - KURA
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Mar 27, 2026 | SCHEDULE 13G/A | The Vanguard Group | 0.0% | 0 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Armistice Capital, LLC | 5.67% | 4,936,000 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Steven Boyd | 5.67% | 4,936,000 | View |
| Feb 09, 2026 | SCHEDULE 13G | STATE STREET CORPORATION | 5.7% | 4,931,090 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND L P | 5.1% | 4,416,545 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | BVF I GP LLC | 5.1% | 4,416,545 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND II LP | 4.2% | 3,640,106 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | BVF II GP LLC | 4.2% | 3,640,106 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Biotechnology Value Trading Fund OS LP | 0.5% | 446,606 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | BVF Partners OS Ltd. | 0.5% | 446,606 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | BVF GP HOLDINGS LLC | 9.3% | 8,056,651 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | BVF PARTNERS L P/IL | 9.99% | 8,677,018 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | BVF INC/IL | 9.99% | 8,677,018 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | LAMPERT MARK N | 9.99% | 8,677,018 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Armistice Capital, LLC | 5.37% | 4,672,000 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Steven Boyd | 5.37% | 4,672,000 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.